Abstract:Abstract Introduction: Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematological malignancies, but its efficacy in patients with glioblastoma (GBM) and other solid tumors is limited due to poor tumor infiltration and an immunosuppressive tumor microenvironment (TME). We have previously shown that blocking vascular endothelial growth factor (VEGF) signaling can normalize tumor vessels, convert the immunosuppressive TME into an immunostimulatory environment, and enhance the efficacy of immunotherapy. This study aimed to investigate whether combining anti-VEGF therapy (B20) with EGFRvIII-targeting CAR-T cell treatment could improve delivery and effectiveness in immunocompetent orthotopic GBM mouse models. Methods: The study utilized two syngeneic mouse GBM cell lines (CT2A and GSC005) engineered to express EGFRvIII, a common neoantigen in human GBM. CAR-T cells were designed to target EGFRvIII. GBM-bearing mice were treated with B20[LS1] followed by EGFRvIII-CAR-T injection. Intravital imaging using two-photon microscopy was employed to track CAR-T cell infiltration into the tumor, while flow cytometry was used to measure the number and function of CAR-T and other immune cells. Results: The combination of B20 and CAR-T cell treatment significantly prolonged the survival of GBM-bearing mice compared to CAR-T cell therapy alone. Intravital imaging revealed that B20 normalized tumor vasculature, leading to a four-fold increase in the number of infiltrated CAR-T cells compared to CAR-T therapy without B20. Flow cytometry analysis showed an increased population of IL-2+ or IFN-γ+ CAR-T cells, indicating that B20 enhanced the anti-tumor function of injected CAR-T cells. Additionally, B20 therapy increased the population of endogenous lymphocytes, specifically Granzyme B+ TNF-α+ CD8 T cells (Cytotoxic T lymphocytes; CTLs) while decreasing FoxP3+ CD4 T cells (Regulatory T cells; Tregs). This indicated that the TME was remodeled to enhance the effect of CAR-T therapy. Conclusions: Our study demonstrated that combining B20 with CAR-T therapy improved their efficacy in GBM mouse models by enhancing CAR-T cell infiltration and reprogramming the TME to activate CAR-T cells and effector T cells. These findings provide compelling evidence for clinically evaluating the combination of anti-VEGF agents with CAR-T cells in GBM patients. We are now building on this approach to enhance CAR-T therapy for breast cancer brain metastasis. We are testing TNBC-targeting CAR-T therapy in murine TNBC-BrM[LS2] using a similar approach. Our hypothesis is that similar to the GBM results, anti-VEGF therapy and adoptive transfer of TNBC-targeting CAR-T cells [LS3] will improve CAR-T cell infiltration, delay tumor growth and prolong survival. This strategy has the potential to enhance emerging cellular immunotherapies' effectiveness in the brain tumor microenvironment. Citation Format: Vasiliki Salameti, Xinyue Dong, Jun Ren, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette, Dai Fukumura, Rakesh K. Jain. Vascular normalization improves the delivery and efficacy of CAR-T cells in mouse brain cancers [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1):Abstract nr A041.

EGFR as a potent CAR T target in triple negative breast cancer brain metastases

EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC

Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor

High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma

SYST-12 D2C7 CAR: A NOVEL CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOMA AND BRAIN METASTASES

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma

EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer

A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases

CAR T cells: engineered immune cells to treat brain cancers and beyond

CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress

Exth-13. Combined Anti-Angiogenic Treatment To Increase Intratumoral Persistence Of Car T-Cells In Lung Cancer Brain Metastases

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Abstract A041: Vascular normalization improves the delivery and efficacy of CAR-T cells in mouse brain cancers

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil

Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell

EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

Abstract LB313: EGFRvIII-targeted alpha therapy shows significant therapeutic efficacy as both a single-agent and in combination with standard of care against preclinical GBM models

Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice